Exclusive: Grifols Pioneer Reveals Secrets Of Plasma Therapy Breakthrough

Verkkothis milestone bolsters the availability of grifols’ plasma therapies; Verkkothe flagship grifols campus is a touchstone of grifols’ leadership in plasma therapeutics, producing about 40% of the company’s total medicinal output. Verkkothe transaction bolsters grifols’ standing as a global leader in fractionation capacity (20 million liters plasma/year) and operator of europe’s largest. Verkkoin an interview by xtalks, jörg schüttrumpf, chief scientific innovation officer (csio) at grifols, sheds light on the company's commitment to innovation in.

Details